Brokerages expect GlaxoSmithKline PLC (NYSE:GSK) to post earnings of $0.68 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for GlaxoSmithKline PLC’s earnings. The lowest EPS estimate is $0.68 and the highest is $0.69. GlaxoSmithKline PLC reported earnings per share of $0.70 during the same quarter last year, which suggests a negative year-over-year growth rate of 2.9%. The firm is expected to report its next earnings report on Wednesday, July 26th.

On average, analysts expect that GlaxoSmithKline PLC will report full-year earnings of $2.85 per share for the current year, with EPS estimates ranging from $2.70 to $2.96. For the next year, analysts expect that the business will report earnings of $2.95 per share, with EPS estimates ranging from $2.86 to $3.07. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow GlaxoSmithKline PLC.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.62. The business had revenue of $9.23 billion during the quarter, compared to the consensus estimate of $9.09 billion. GlaxoSmithKline PLC had a return on equity of 113.31% and a net margin of 5.48%.

A number of brokerages have recently commented on GSK. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday. Citigroup Inc. lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Finally, ValuEngine lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $46.00.

A number of hedge funds have recently modified their holdings of GSK. Greenleaf Trust boosted its stake in shares of GlaxoSmithKline PLC by 1.5% in the second quarter. Greenleaf Trust now owns 11,232 shares of the pharmaceutical company’s stock valued at $484,000 after buying an additional 170 shares in the last quarter. Investment Partners Ltd. OH ADV boosted its stake in shares of GlaxoSmithKline PLC by 0.8% in the second quarter. Investment Partners Ltd. OH ADV now owns 9,491 shares of the pharmaceutical company’s stock valued at $409,000 after buying an additional 76 shares in the last quarter. Ipswich Investment Management Co. Inc. boosted its stake in shares of GlaxoSmithKline PLC by 0.6% in the second quarter. Ipswich Investment Management Co. Inc. now owns 21,720 shares of the pharmaceutical company’s stock valued at $937,000 after buying an additional 140 shares in the last quarter. Guardian Investment Management boosted its stake in shares of GlaxoSmithKline PLC by 2.4% in the second quarter. Guardian Investment Management now owns 21,100 shares of the pharmaceutical company’s stock valued at $910,000 after buying an additional 500 shares in the last quarter. Finally, Juncture Wealth Strategies LLC boosted its stake in shares of GlaxoSmithKline PLC by 1.5% in the second quarter. Juncture Wealth Strategies LLC now owns 6,700 shares of the pharmaceutical company’s stock valued at $289,000 after buying an additional 100 shares in the last quarter. 8.98% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/07/24/0-68-earnings-per-share-expected-for-glaxosmithkline-plc-gsk-this-quarter.html.

GlaxoSmithKline PLC (NYSE GSK) traded down 0.98% during trading on Monday, reaching $42.24. The company had a trading volume of 2,980,544 shares. The firm has a 50-day moving average price of $43.28 and a 200 day moving average price of $41.70. The stock has a market cap of $103.19 billion, a P/E ratio of 47.25 and a beta of 1.05. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $45.58.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, July 13th. Shareholders of record on Friday, May 12th were paid a dividend of $0.483 per share. This represents a $1.93 annualized dividend and a yield of 4.57%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend was Wednesday, May 10th. GlaxoSmithKline PLC’s dividend payout ratio is currently 233.74%.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Get a free copy of the Zacks research report on GlaxoSmithKline PLC (GSK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.